Monoclonal antibody reduces Cdiff recurrence

By  |  January 20, 2010 | 

In this trial of 200 patients with active Cdiff infection, they were randomized to placebo or a single IV infusion of a monoclonal antibody against toxin A and B, in addition to standard treatment with either metronidazole or vancomycin. Those in the antibody group had lower risk of recurrence at 84 days (7% vs 25%) with no difference in adverse events. A single infusion of monoclonal antibody significantly reduces the risk of recurrent Cdiff infection (abstract).

Leave A Comment

About the Author: Danielle Scheurer

Danielle Scheurer
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.


Related Posts

By  | June 29, 2013 |  0
This large systematic review found rectal NSAIDs significantly reduced the risk of post-ERCP pancreatitis compared to pancreatic duct stents (abstract).
By  | June 22, 2013 |  0
This large population-based cohort found the most common causes of drug induced liver injury to be augmentin and diclofenac, followed by herbal and nutritional supplements (abstract).
By  | May 25, 2013 |  0
This large trial of patients with a relative contraindication for enteral feeds were randomized to early TPN or usual care. There were no differences in the groups in 60 day mortality or LOS, but those on TPN did have a shorter time ventilated and less muscle/fat loss. It is unclear based on this trial if […]